Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS

Remission Rates Double At Phase II

Executive Summary

Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.

You may also be interested in...



Keeping Track: The Breakthrough Designations Of Summer Eschew Phase I

The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker

STING, SUMO In Spotlight As Takeda Showcases Oncology Progress

Japanese firm points to progress in its cancer pipeline as it looks to launch three new molecular entities in the sector by 2024 and investigates novel modalities.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel